<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940810-0-00019</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective September 9, 1994; written comments, notice of participation, and requests for a hearing by September 9, 1994; data, information, and analyses to justify a hearing by October 11, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 430, 436, and 455</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 94N&hyph;0184]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Antibiotics Drugs; Rifabutin and Rifabutin Capsules <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the antibiotic drug regulations to include accepted standards for a new antibiotic drug, rifabutin, and the use of the antibiotic drug in a dosage form, rifabutin capsules. The manufacturer has supplied sufficient data and information to establish its safety and efficacy. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective September 9, 1994; written comments, notice of participation, and requests for a hearing by September 9, 1994; data, information, and analyses to justify a hearing by October 11, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> James Timper, Center for Drug Evaluation and Research (HFD&hyph;520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;6714. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA has evaluated data submitted in accordance with regulations promulgated under section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357), as amended, with respect to a request for approval of (1) a new antibiotic drug, rifabutin, and (2) its use in a dosage form, rifabutin capsules. The agency has concluded that the data supplied by the manufacturer concerning these antibiotic drugs are adequate to establish their safety and efficacy when used as directed in the labeling and that the regulations should be amended in 21 CFR parts 430, 436, and 455 to include accepted standards for these products. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Submitting Comments and Filing Objections <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> This final rule announces standards that FDA has accepted in a request for approval of an antibiotic drug. Because this final rule is not controversial and because when effective it provides notice of accepted standards, FDA finds that notice and comment procedure is unnecessary and not in the public interest. This final rule, therefore, is effective September 9, 1994. However, interested persons may, on or before September 9, 1994, submit written comments to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file (1) on or before September 9, 1994, a written notice of participation and request for a hearing, and (2) on or before October 11, 1994, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for a hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for a hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch. <!-- PJG 0012 frnewline --> The procedures and requirements governing this order, a notice of participation and request for a hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300. <!-- PJG 0012 frnewline --> All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Part 430 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Administrative practice and procedure, Antibiotics. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Parts 436 and 455 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Antibiotics. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 430, 436, and 455 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 430_ANTIBIOTIC DRUGS; GENERAL <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 430 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 201, 501, 502, 503, 505, 507, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 353, 355, 357, 371); secs. 215, 301, 351 of the Public Health Service Act (42 U.S.C. 216, 241, 262). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 430.4 is amended by adding new paragraph (a)(69) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;430.4  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Definitions of antibiotic substances.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) * * * <!-- PJG 0012 frnewline --> (69)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Rifabutin is an antibiotic substance having the chemical structure described by the following name: (9 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,12 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,14 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,15 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,16 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,17 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,18 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,19 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , 20 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,21 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,22 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , 24 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )-6,16, 18,20-tetrahydroxy-1 <!-- PJG 0020 minuteslatlong --> &rsquo;-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -furo[2 <!-- PJG 0020 minuteslatlong --> &rsquo;,3 <!-- PJG 0020 minuteslatlong --> &rsquo;:7,8]naphth[1,2-d]imidazole-2,4 <!-- PJG 0020 minuteslatlong --> &rsquo;-piperidine]-5,10,26-(3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,9 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )-trione-16-acetate. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. Section 430.5 is amended by adding new paragraphs (a)(104) and (b)(106) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;430.5  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Definitions of master and working standards.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) * * * <!-- PJG 0012 frnewline --> (104)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The term ``rifabutin master standard'' means a specific lot of rifabutin that is designated by the Commissioner as the standard of comparison in determining the potency of the rifabutin working standard. <!-- PJG 0012 frnewline --> (b) * * * <!-- PJG 0012 frnewline --> (106)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The term ``rifabutin working standard'' means a specific lot of a homogeneous preparation of rifabutin.  <!-- PJG 0012 frnewline --> 4. Section 430.6 is amended by adding new paragraph (b)(106) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;430.6  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Definitions of the terms ``unit'' and ``microgram'' as applied to antibiotic substances. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b) * * * <!-- PJG 0012 frnewline --> (106)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The term ``microgram'' applied to rifabutin means the rifabutin (potency) contained in 1.022 micrograms of the rifabutin master standard. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 436_TESTS AND METHODS OF ASSAY OF ANTIBIOTIC AND ANTIBIOTIC-CONTAINING DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 5. The authority citation for 21 CFR part 436 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> : Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 6. Section 436.215 is amended by alphabetically adding a new entry to the table in paragraph (b) and by adding new paragraph (c)(18) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;436.215  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Dissolution test. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b) * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 5,L1,i1,s33,35,17,17,17 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Dosage form  <!-- PJG 007 0150 intable --> 1Dissolution medium  <!-- PJG 007 0150 intable --> 1Rotation rate1  <!-- PJG 007 0150 intable --> 1Sampling time(s)  <!-- PJG 007 0150 intable --> 1Apparatus  <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Rifabutin capsules  <!-- PJG 007 0104 intable --> 900 mL 0.01 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0034 unknown --> hydrochloric acid  <!-- PJG 007 0104 intable --> 100  <!-- PJG 007 0104 intable --> 45 min  <!-- PJG 007 0104 intable --> 1  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> 1Rotation rate of basket or paddle stirring element (revolutions per minute). <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c) * * * <!-- PJG 0012 frnewline --> (18)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of the working standard solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Accurately weigh approximately 45 milligrams of the rifabutin working standard into a suitable-sized volumetric flask. Dissolve and dilute to volume with 0.01 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid (prepared by diluting 5.0 milliliters of hydrochloric acid (37 percent) to 6 liters with distilled water) to obtain a concentration of approximately 13 micrograms rifabutin activity per milliliter. <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Forty-five minutes after the beginning of the rotation, withdraw a 10-milliliter aliquot from the vessel. Dilute a 2-milliliter portion of the sample to 25 milliliters with 0.01 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid. <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Procedure <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Using a suitable spectrophotometer and 0.01 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid as the blank, determine the absorbance of each standard and sample solution at the absorbance maximum at approximately 280 nanometers. Determine the exact position of the absorbance maximum for the particular instrument used. <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Determine the total amount of rifabutin dissolved as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),g1,t1,aw,s6,r3,r90 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> T <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->   <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> c <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 900 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 1,000 <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> T <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Total milligrams of rifabutin activity dissolved; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of sample; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of the standard;  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> c <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Rifabutin activity of the working standard solution in micrograms per milliliter; and <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Dilution factor of the sample filtrate. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7. New &sect;&sect;436.369 and 436.370 are added to subpart F to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;436.369  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Thin layer chromatography test for free  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> -isobutylpiperidone content in rifabutin. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Equipment <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Chromatography tank <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . A rectangular tank, approximately 23 X 23 X 9 centimeters, with a glass solvent trough on the bottom and a tight-fitting cover. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Iodine vapor chamber <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . A rectangular tank, approximately 23 X 23 X 9 centimeters, with a suitable cover, containing iodine crystals. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Plates <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Use 20 X 20 centimeter thin layer chromatography plates coated with silica gel 60F 254 or equivalent to a thickness of 250 microns. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Reagents <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Developing solvent <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Mix petroleum ether (b.p. 60 to 80  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=8 f=1 -->  <!-- PJG 0253 grid5678 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> C) and acetone in volumetric proportions of 100:30, respectively.  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Spray solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare a 1 percent solution of soluble starch in water (containing 0.01 percent mercuric iodide). <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of spotting solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare a solution of the rifabutin sample in 1:1 chloroform/methanol to contain 10 milligrams per milliliter.  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standard solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare a solution of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone standard in 1:1 chloroform/methanol to contain 1 milligram per milliliter. Transfer aliquots of 0.5, 1.0, 2.0, 5.0, and 10.0 milliliters into separate 100-milliliter volumetric flasks and dilute to volume with 1:1 chloroform/methanol. These solutions contain, respectively, the equivalent of 0.05, 0.1, 0.2, 0.5, and 1.0 percent of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone. <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Procedure <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Pour 100 milliliters of developing solvent into the glass trough on the bottom of the unlined chromatography tank. Cover and seal the tank. Allow it to equilibrate while the plate is being prepared. Prepare a plate as follows: on a line 2.0 centimeters from the base of the thin layer chromatography plate, and at intervals of 2.0 centimeters, apply 10 microliters of each of the standard solutions and the sample solution prepared as directed above. After the spots are thoroughly dry, place the plate into the trough in the bottom of the tank. Cover and tightly seal the tank, allow the solvent front to travel about 15 centimeters from the starting line and then remove the plate from the tank. Air dry the plate. Warm the iodine vapor chamber to vaporize the iodine crystals and place the dry plate in the iodine vapor chamber until the spots are visible (usually about 5 minutes). Remove the plate from the iodine vapor chamber and spray with 1 percent starch solution. <!-- PJG 0012 frnewline --> (e)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Evaluation <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Measure the distance the solvent front traveled from the starting line and the distance the spots are from the starting line. Calculate the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> f <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  value by dividing the latter by the former.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone has an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> f <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  value of about 0.3. Rifabutin has an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> f <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  value of about 0.1. Compare the size and intensity of any  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone spots in the sample lane with the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone spots in the standard lanes, and report the percentage of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone in the sample. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;436.370  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Spectrophotometric identity test for rifabutin capsules. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Equipment <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . A suitable spectrophotometer capable of recording the ultraviolet spectrum in the 200 to 400 nanometer range, using suitable quartz cells of 1 centimeter pathlength. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of working standard and sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Working standard solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Suspend approximately 200 milligrams of rifabutin working standard in 20 milliliters of methanol and sonicate for approximately 5 minutes. Filter the resulting solution through a suitable 0.5 micrometer filter. Transfer a 2-milliliter aliquot of the filtered solution to a 100-milliliter volumetric flask and fill to volume with methanol. Further dilute with methanol to obtain a solution containing 20 micrograms of rifabutin activity per milliliter. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Empty and combine the contents of five capsules. Suspend a quantity of the capsule contents equivalent to 200 milligrams of rifabutin in 20 milliliters of methanol. Sonicate for about 5 minutes and then filter through an appropriate 0.5 micrometer filter. Transfer a 2-milliliter aliquot to a 100-milliliter volumetric flask and dilute to volume with methanol. Further dilute with methanol to obtain a solution containing 20 micrograms of rifabutin activity per milliliter (estimated).  <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Procedure <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Using a suitable spectrophotometer equipped with 1.0 centimeter cells and methanol as the blank, determine the absorbance spectra of the working standard and sample solutions over the ultraviolet range of 250 to 300 nanometers. <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Evaluation <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Compare the spectrum of the sample to that of the working standard. The identity of the rifabutin capsules is confirmed by quantitative comparison of the two spectra with an absorbance maximum being observed at about 275 nanometers. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 455_CERTAIN OTHER ANTIBIOTIC DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 8. The authority citation for 21 CFR part 455 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> : Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 9. New &sect;455.88 is added to subpart A to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;455.88  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Rifabutin. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Rifabutin is an amorphous red-violet powder. It is (9 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,12 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,14 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,15 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,16 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , <!-- PJG 0012 frnewline --> 17 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,18 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,19 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,20 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,21 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> 22 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> ,24 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> )- <!-- PJG 0012 frnewline --> 6,16,18,20-tetrahydroxy-1 <!-- PJG 0020 minuteslatlong --> &rsquo;- <!-- PJG 0012 frnewline --> isobutyl-14-methoxy- <!-- PJG 0012 frnewline --> 7,9,15,17,19,21,25-heptamethylspiro[9,4-(epoxypentadeca <!-- PJG 0012 frnewline --> [1,11,13]trienimino)- <!-- PJG 0012 frnewline --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> -furo[2 <!-- PJG 0020 minuteslatlong --> &rsquo;,3 <!-- PJG 0020 minuteslatlong --> &rsquo;:7,8]  <!-- PJG 0012 frnewline --> naphth[1,2-d]imidazole-2,4 <!-- PJG 0020 minuteslatlong --> &rsquo;-piperidine]-5,10,26-(3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> ,9 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> )-trione-16-acetate. It is very slightly soluble in water, sparingly soluble in ethanol, and soluble in chloroform and methanol. It is so purified and dried that: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i) Its potency is not less than 950 micrograms and not more than 1,020 micrograms of rifabutin activity per milligram on an anhydrous basis.  <!-- PJG 0012 frnewline --> (ii) Its content for the four major related substances detected by high-performance liquid chromatography (HPLC) is not more than 1.0 percent each. All other unknown related substances are not more than 0.5 percent. The total of all related substances is not more than 3.0 percent. <!-- PJG 0012 frnewline --> (iii) Its moisture content is not more than 2.5 percent.  <!-- PJG 0012 frnewline --> (iv) Its  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone content is not more than 0.5 percent. <!-- PJG 0012 frnewline -->  (v) It gives a positive identity test. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on the batch for rifabutin potency, related substances, moisture,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone, and identity.  <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: 10 packages each containing approximately 300 milligrams. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Potency <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.216 of this chapter, using ambient temperature, an ultraviolet detection system operating at a wavelength of 254  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  1 nanometers, an 11 centimeters X 4.7 millimeters (i.d.) column packed with microparticulate (5 to 7 micrometers in diameter) packing material such as octylsilane chemically bonded to porous silica (U.S. Pharmacopeia designation L7), a flow rate of about 1.0 milliliter per minute, and a manual or automatic injector capable of injecting 10 microliters. The retention time for rifabutin is between 9 and 11 minutes. Reagents; working standard, sample, and resolution solutions; system suitability requirements; and calculations are as follows: <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Reagents <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hydrochloric acid, 2N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dilute 85 milliliters of hydrochloric acid (37 percent) with distilled water to 500 milliliters. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Potassium dihydrogen phosphate, 0.1M <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare a solution containing 15.4 grams of potassium dihydrogen phosphate monohydrate (potassium phosphate monobasic) per liter of distilled water. <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sodium hydroxide, 2N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve 8 grams of sodium hydroxide pellets in 100 milliliters of distilled water. <!-- PJG 0012 frnewline --> (D)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Mobile phase <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Acetonitrile:phosphate buffer, pH 6.5, 50:50. Mix equal quantities of acetonitrile and 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> M <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  potassium dihydrogen phosphate and adjust to an apparent pH of 6.5  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  0.1 by dropwise addition of 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  sodium hydroxide. Filter through a suitable filter capable of removing particulate matter 0.5 micron in diameter and degas it just prior to its introduction into the chromatograph. Slight adjustments of the mobile phase components ratio may be made in order to meet the system suitability requirements described in the system suitability tests in paragraph (b)(1)(iii) of this section. <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of working standard, sample, and resolution test solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Working standard solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Accurately weigh approximately 25 milligrams of the rifabutin working reference standard into a 50-milliliter volumetric flask. Add 5 milliliters of acetonitrile. Dissolve and dilute to volume with mobile phase and mix to obtain a solution having a known concentration of about 0.5 milligram of rifabutin per milliliter. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Accurately weigh approximately 25 milligrams of sample into a 50-milliliter volumetric flask. Add 5 milliliters of acetonitrile. Dissolve and dilute to volume with mobile phase and mix to obtain a solution containing 0.5 milligram of rifabutin per milliliter (estimated).  <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Resolution test solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve approximately 10 milligrams of rifabutin in 2 milliliters of methanol and add 1 milliliter of 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  sodium hydroxide. Allow to stand for 3 to 4 minutes and then add 1 milliliter of 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid. Mix and dilute to 50 milliliters with mobile phase. Store aliquots of this solution in the frozen state for future use.  <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> System suitability requirements <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Using the apparatus and conditions described in this section, test the chromatographic system by injecting the resolution test solution. The chromatogram shows one major degradation peak and two minor degradation peaks eluting at relative retention times (RRT) of 0.5&hyph;0.6, 0.65&hyph;0.75, and 0.8&hyph;0.9, respectively, followed by the rifabutin peak. <!-- PJG 0012 frnewline --> (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Asymmetry factor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The asymmetry factor ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) is satisfactory if it is not less than 1.0 and not more than 4.0 for the rifabutin peak. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Efficiency of the column <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The absolute efficiency ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> h <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) is satisfactory if it is not more than 11 for the rifabutin peak, equivalent to 2,000 theoretical plates for a 11-centimeter column of 5-micrometer particles. <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Resolution factor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The resolution factor ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) between the peak for rifabutin and its closest eluting degradation product (generated in situ as described in paragraph (b)(1)(iii) of this section and eluting at RRT of 0.8&hyph;0.9) is satisfactory if it is not less than 1.3.  <!-- PJG 0012 frnewline --> (D)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Coefficient of variation (relative standard deviation <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ). The coefficient of variation ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  in percent of 5 replicate injections of the rifabutin working standard solution) is satisfactory if it is not more than 2.0 percent. If the system suitability parameters have been met, then proceed as described in &sect;436.216(b) of this chapter.  <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the micrograms of rifabutin per milligram of sample on an anhydrous basis as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s28,r5,r45 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Micrograms of rifabutin per  <!-- PJG 0034 unknown --> milligram  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 100  <!-- PJG 0012 frnewline -->   <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X (100^ <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 --> ) <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the rifabutin peak in the chromatogram of the sample (at a retention time equal to that observed for the standard); <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the rifabutin peak in the chromatogram of the rifabutin working standard; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Rifabutin activity in the rifabutin working standard solution in micrograms per milliliter; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Milligrams of sample per milliliter of sample solution; and  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Percent moisture content of the sample. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Related substances <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in paragraph (b)(1) of this section for potency using the sample prepared as described in paragraph (b)(1)(ii)(B) of this section and calculating the amounts of related substances as follows.  <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the percentage of related substances as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s30,r5,r18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Percent individual HPLC-related  <!-- PJG 0034 unknown --> substance  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> i <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  x 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s30,r5,r18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Percent total HPLC- <!-- PJG 0034 unknown --> related substances  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  x 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> i <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the individual related substance peak; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = The sum of areas of all peaks minus the area due to the rifabutin peak and solvent front peak; and <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = The sum of areas of all peaks in the chromatogram excluding the solvent peak. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (ii) [Reserved] <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moisture <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.201 of this chapter. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N-Isobutylpiperidone <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.369 of this chapter. <!-- PJG 0012 frnewline --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (i) Proceed as directed in &sect;436.211 of this chapter, using the sample preparation method described in paragraph (b)(1) of that section using a 1 to 2 percent mixture in potassium bromide. <!-- PJG 0012 frnewline --> (ii) The identity of rifabutin is confirmed by the qualitative comparison of the HPLC of the sample to the rifabutin working standard as directed in paragraph (b)(1) of this section.  <!-- PJG 0012 frnewline --> 10. New &sect;455.188 is added to subpart B to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;455.188  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Rifabutin capsules. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Rifabutin capsules are gelatin capsules containing rifabutin with a suitable and harmless filler and with or without binders, lubricants, and stabilizers. Each capsule contains rifabutin equivalent to 150 milligrams of rifabutin. Its rifabutin content is satisfactory if it is not less than 90 percent and not more than 110 percent of the number of milligrams of rifabutin that it is represented to contain. Its content of the four major related substances detected by high-performance liquid chromatography (HPLC) is not more than 1.0 percent each. All other unknown related substances are not more than 0.5 percent. The total of all related substances is not more than 4.5 percent. It passes the dissolution test if the quantity (Q) dissolved is 75 percent at 45 minutes. It passes the identity test. The rifabutin used conforms to the standards prescribed by &sect;455.88(a)(1). <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on: <!-- PJG 0012 frnewline --> (A) The rifabutin used in making the batch for potency, related substances, moisture,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -isobutylpiperidone, and identity.  <!-- PJG 0012 frnewline --> (B) The batch for content, related substances, dissolution, and identity. <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: <!-- PJG 0012 frnewline --> (A) The rifabutin used in making the batch: 10 packages, each containing approximately 300 milligrams. <!-- PJG 0012 frnewline --> (B) The batch: A minimum of 30 capsules. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Rifabutin content <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;455.88(b)(1), preparing the sample solution and calculating the rifabutin content as follows: <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Empty 20 capsules, collecting the contents quantitatively. Weigh the powder and determine the average capsule fill weight. Mix the powder and accurately weigh a portion containing the equivalent of about 25 milligrams of rifabutin into a 50-milliliter volumetric flask. Add 5 milliliters of acetonitrile. Dilute to volume with mobile phase and mix to yield a solution containing 0.5 milligram of rifabutin per milliliter (estimated). Filter through a suitable filter capable of removing particulate matter 0.5 micron in diameter prior to injection into the chromatographic system. <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the rifabutin content as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s30,r5,r35 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Milligrams of rifabutin per capsule  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG ITAG l=11 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> W <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  X 1,000  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the rifabutin peak in the chromatogram of the sample (at a retention time equal to that observed for the standard); <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the rifabutin peak in the chromatogram of the rifabutin working standard; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Milligrams of rifabutin working standard per milliliter of standard solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Milligrams of sample per milliliter of sample solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Rifabutin activity in the rifabutin working standard solution in micrograms per milliliter; and <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> W <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Average capsule fill weight in milligrams. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Related substances <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in paragraph (b)(1) of this section for rifabutin content using the sample prepared as described in paragraph (b)(1)(i) of this section and calculating the amounts of related substances as follows. <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the percentage of related substances as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s30,r5,r18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Percent individual HPLC-related  <!-- PJG 0034 unknown --> substance  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG ITAG l=11 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> i <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  x 100 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,t1,s30,r5,r18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Percent total HPLC- <!-- PJG 0034 unknown --> related substances  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1 <!-- PJG ITAG l=22 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  x 100 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> i <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the individual related substance peak; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = The sum of areas of all peaks minus the area due to the rifabutin peak and solvent front peak; and <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> t <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = The sum of areas of all peaks in the chromatogram excluding the solvent peak. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (ii) [Reserved] <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Dissolution test <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.215 of this chapter. The quantity (Q) (the amount of rifabutin activity dissolved) is 75 percent within 45 minutes. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (i) The retention time of the rifabutin response in the HPLC procedure described in paragraph (b)(1) of this section as applied to the sample solution compares qualitatively to that of the rifabutin reference standard. <!-- PJG 0012 frnewline --> (ii) The identity of rifabutin capsules is also confirmed by the spectrophotometric identity test described in &sect;436.370 of this chapter. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 1, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Stephanie R. Gray, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Acting Director, Office of Compliance, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;19484 Filed 8&hyph;9&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            